Loading clinical trials...

Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer

NCT01514669•University of Arkansas

View on ClinicalTrials.gov

Summary

The purpose of this research study is to compare profiles in the blood and tears of patients with and without prostate cancer with the goal of developing a method of separating men with aggressive and non-aggressive disease.

Eligibility

Age

35 - 85 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. Male, 35-85 years old
•2. Patients who present for the evaluation of an abnormal exam or test (elevated PSA, abnormal DRE, etc.)
•3. Patients who present for the evaluation of a palpable nodule or induration on prostate exam
•4. Patients who meet the requirements of Group 1, 2, or 3 of the protocol

Exclusion Criteria

•1. Patient \< 35 or \> 85 years of age
•2. Concurrent eye infection or trauma, including active conjunctivitis
•3. Abnormal production of tears (too much or too little)
•4. Any other conditions the PI or staff feels will not fulfill the criteria for study entry or will place the subject in a harmful environment
•5. Atypia on prostate biopsy report

Locations (1)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Key Dates

Start Date

January 1, 2012

Primary Completion Date

February 1, 2027

Completion Date

February 1, 2027

Last Updated

October 10, 2025

Enrollment

ESTIMATED participants

Conditions

Prostate Cancer

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE2

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498

Metastatic Castration-Resistant Prostate Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 10, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC